Obsidian Therapeutics, Inc. products

Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® technology.

Our proprietary cytoDRiVE® platform leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule.